



## Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 9, 2024

**Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema's KAT6 inhibitor, in combination with palazestrant and other targeted agents**

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- [Olema Pharmaceuticals, Inc.](#) ("Olema" or "Olema Oncology", Nasdaq: OLM), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that it will be presenting multiple posters during the 36<sup>th</sup> EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) taking place October 23-25, 2024, in Barcelona, Spain.

Details of the ENA 2024 poster presentations are:

- Title:** Combining palazestrant, a CERAN, and everolimus, an mTOR inhibitor, enhances tumor suppression in ER+/HER2- breast cancer models
- Poster/Abstract:** 211
- Session:** Poster Session 300, Exhibition Hall
- Date/Time:** Thursday, October 24, 2024, from 09:00 to 17:30 CEST
- 
- Title:** Combining palazestrant, a CERAN, and capivasertib, a pan-AKT inhibitor, enhances tumor suppression in ER+/HER2- breast cancer models
- Poster/Abstract:** 212
- Session:** Poster Session 300, Exhibition Hall
- Date/Time:** Thursday, October 24, 2024, from 09:00 to 17:30 CEST
- 
- Title:** Combining OP-3136, a KAT6 inhibitor, with endocrine therapy and CDK4/6 inhibitor enhances anti-tumor activity in ER+/HER2- breast cancer models
- Poster/Abstract:** 230
- Session:** Poster Session 300, Exhibition Hall
- Date/Time:** Thursday, October 24, 2024, from 09:00 to 17:30 CEST

Additional information, including abstracts for these presentations, can be found on the [ENA website](#). Copies of the posters will be made available on the [Publications](#) page of Olema's website in alignment with the Symposium's embargo policy.

### About Palazestrant (OP-1250)

Palazestrant (OP-1250) is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, CNS penetration, and combinability with CDK4/6 inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated both as a single agent in an ongoing Phase 3 clinical trial, OPERA-01, and in Phase 1/2 combination studies with CDK4/6 inhibitors (palbociclib and ribociclib), a PI3Ka inhibitor (alpelisib), and an mTOR inhibitor (everolimus). For more information on OPERA-01, please visit [www.opera01study.com](http://www.opera01study.com).

### About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving

outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at [www.olema.com](http://www.olema.com).

Contact:

Courtney O'Konek, Vice President, Corporate Communications

[media@olema.com](mailto:media@olema.com)